PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2022.10582023552626-635Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker AnalysisTing Xu, Xicheng Wang, Ying Xin, Zhenghang Wang, Jifang Gong, Xiaotian Zhang, Yanyan Li, Congcong Ji, Yu Sun, Feilong Zhao, Depei Huang, Yuezong Bai, Jian Li, Lin Shenhttp://e-crt.org/upload/pdf/crt-2022-1058.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.1058, http://e-crt.org/upload/pdf/crt-2022-1058.pdf
Annals of Oncology10.1016/j.annonc.2020.08.2066202031S460-S461523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancerJ. Strickler, K. Ng, A. Cercek, C. Fountzilas, F. Sanchez, J. Hubbard, C. Wu, M. Stecher, L.N. Walker, T. Bekaii-Saabhttps://api.elsevier.com/content/article/PII:S0923753420420630?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420420630?httpAccept=text/plain
10.21203/rs.3.rs-1752120/v12022Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trialXiao-Feng Xie, Qiu-Yi Zhang, Jia-Yi Huang, Li-Ping Chen, Xiao-Feng Lan, Xue Bai, Lin Song, Shui-Ling Xiong, Si-Jia Guo, Cai-Wen Duhttps://www.researchsquare.com/article/rs-1752120/v1, https://www.researchsquare.com/article/rs-1752120/v1.html
Annals of Oncology10.1016/s0923-7534(20)32976-8201223ix142Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet)M. Andersson, J.M. Lopez-Vega, L. Del Mastro, T. Petit, L. Mitchell, C. Pelizon, E.A. Perezhttps://api.elsevier.com/content/article/PII:S0923753420329768?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420329768?httpAccept=text/plain
Annals of Oncology10.1016/j.annonc.2022.07.283202233S648-S649244P Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II studyY. Yin, X. Wu, X. Huang, W. Li, Y. Hua, Y. Lianghttps://api.elsevier.com/content/article/PII:S0923753422021342?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753422021342?httpAccept=text/plain
Clinical Colorectal Cancer10.1016/j.clcc.2022.07.0032022214347-353Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G StudyJinjia Chang, Midie Xu, Chenchen Wang, Dan Huang, Zhe Zhang, Zhiyu Chen, Xiaodong Zhu, Wenhua Lihttps://api.elsevier.com/content/article/PII:S1533002822000718?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1533002822000718?httpAccept=text/plain
Annals of Oncology10.1016/j.annonc.2022.07.227202233S624192P A phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC)Y. Yang, L. Jin, N. Rao, C. Gong, S. Li, Y. Li, J. Wu, J. Zhao, L. Ding, Q. Liuhttps://api.elsevier.com/content/article/PII:S0923753422020786?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753422020786?httpAccept=text/plain
Breast Cancer Research10.1186/bcr36612014163Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancerEdith A Perez, Sara A Hurvitz, Lukas C Amler, Kirsten E Mundt, Vivian Ng, Ellie Guardino, Luca Giannihttp://link.springer.com/content/pdf/10.1186/bcr3661.pdf, http://link.springer.com/article/10.1186/bcr3661/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr3661.pdf
Annals of Oncology10.1093/annonc/mdx697.083201728ix93Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumabKazuteru Hatanaka, Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, Minoru Uebayashi, Masakazu Abe, Michio Nakamura, Hiroyuki Okuda, Yuh Sakata, Yoshito Komatsuhttps://api.elsevier.com/content/article/PII:S0923753420353230?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420353230?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_9/mdx697.083/21525446/mdx697.083.pdf
Annals of Oncology10.1016/j.annonc.2022.07.1323202233S11001205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimenG.Y. Ku, M. Di Bartolomeo, E. Smyth, I. Chau, H. Park, S. Siena, S. Lonardi, Z.A. Wainberg, J.A. Ajani, J. Chao, F. Barlaskar, Y. Kawaguchi, A. Qin, J. Singh, G. Meinhardt, E. Van Cutsemhttps://api.elsevier.com/content/article/PII:S092375342203174X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375342203174X?httpAccept=text/plain